Categories Health Care

Solid Biosciences tumbles 38% to hit historic low

Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its lead investigational drug, SGT-001, spurred serious adverse event in a patient.

The drug has been in development to treat a rare muscle disorder known as Duchenne. However, in its latest patient, the drug caused certain liver problems, besides gastrointestinal infection.

Image for representation (Photo by Drew Hays on Unsplash)

Solid Biosciences added that the patient is currently doing well and has resumed normal activities.    

The company, which does not have any revenues as of now, said its research and development expenses doubled during the quarter to $23.3 million, all attributable to SGT-001.

Net loss almost doubled to $29.6 million, or 85 cents per share, hurt by the higher expenses.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

The company, which started trading in January last year, has since declined 62% and is currently trading at an all-time low.

CEO Ilan Ganot said, “We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients.”

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top